227 related articles for article (PubMed ID: 29347996)
1. The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial.
Scherer RW; Drye L; Mintzer J; Lanctôt K; Rosenberg P; Herrmann N; Padala P; Brawman-Mintzer O; Burke W; Craft S; Lerner AJ; Levey A; Porsteinsson A; van Dyck CH;
Trials; 2018 Jan; 19(1):46. PubMed ID: 29347996
[TBL] [Abstract][Full Text] [Related]
2. Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.
Mintzer J; Lanctôt KL; Scherer RW; Rosenberg PB; Herrmann N; van Dyck CH; Padala PR; Brawman-Mintzer O; Porsteinsson AP; Lerner AJ; Craft S; Levey AI; Burke W; Perin J; Shade D;
JAMA Neurol; 2021 Nov; 78(11):1324-1332. PubMed ID: 34570180
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.
Rosenberg PB; Lanctôt KL; Drye LT; Herrmann N; Scherer RW; Bachman DL; Mintzer JE; ADMET Investigators
J Clin Psychiatry; 2013 Aug; 74(8):810-6. PubMed ID: 24021498
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for apathy in Alzheimer's disease.
Ruthirakuhan MT; Herrmann N; Abraham EH; Chan S; Lanctôt KL
Cochrane Database Syst Rev; 2018 May; 5(5):CD012197. PubMed ID: 29727467
[TBL] [Abstract][Full Text] [Related]
5. Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments.
Lanctôt KL; Scherer RW; Li A; Vieira D; Coulibaly H; Rosenberg PB; Herrmann N; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer JE
Am J Geriatr Psychiatry; 2021 Jan; 29(1):81-89. PubMed ID: 32565008
[TBL] [Abstract][Full Text] [Related]
6. Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).
Drye LT; Scherer RW; Lanctôt KL; Rosenberg PB; Herrmann N; Bachman D; Mintzer JE;
Am J Geriatr Psychiatry; 2013 Jun; 21(6):549-59. PubMed ID: 23567407
[TBL] [Abstract][Full Text] [Related]
7. Adverse effects of methylphenidate for apathy in patients with Alzheimer's disease (ADMET2 trial).
Zeng L; Perin J; Gross AL; Shade D; Lanctôt KL; Lerner AJ; Mintzer JE; Brawman-Mintzer O; Padala PR; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Herrmann N; Rosenberg PB
Int J Geriatr Psychiatry; 2024 Jun; 39(6):e6108. PubMed ID: 38858522
[TBL] [Abstract][Full Text] [Related]
8. Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).
Lanctôt KL; Chen C; Mah E; Kiss A; Li A; Shade D; Scherer RW; Vieira D; Coulibaly H; Rosenberg PB; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey A; Burke WJ; Mintzer J; Herrmann N
Int Psychogeriatr; 2023 Nov; 35(11):664-672. PubMed ID: 37066690
[TBL] [Abstract][Full Text] [Related]
9. Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial.
Padala PR; Padala KP; Lensing SY; Ramirez D; Monga V; Bopp MM; Roberson PK; Dennis RA; Petty F; Sullivan DH; Burke WJ
Am J Psychiatry; 2018 Feb; 175(2):159-168. PubMed ID: 28945120
[TBL] [Abstract][Full Text] [Related]
10. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge.
Herrmann N; Rothenburg LS; Black SE; Ryan M; Liu BA; Busto UE; Lanctôt KL
J Clin Psychopharmacol; 2008 Jun; 28(3):296-301. PubMed ID: 18480686
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Psychostimulants for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
Kishi T; Sakuma K; Iwata N
Pharmacopsychiatry; 2020 Apr; 53(3):109-114. PubMed ID: 32000270
[TBL] [Abstract][Full Text] [Related]
12. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial.
Lanctôt KL; Chau SA; Herrmann N; Drye LT; Rosenberg PB; Scherer RW; Black SE; Vaidya V; Bachman DL; Mintzer JE
Int Psychogeriatr; 2014 Feb; 26(2):239-46. PubMed ID: 24169147
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.
Lanctôt KL; Rivet L; Tumati S; Perin J; Sankhe K; Vieira D; Mintzer J; Rosenberg PB; Shade D; Lerner AJ; Padala PR; Brawman-Mintzer O; van Dyck CH; Porsteinsson AP; Craft S; Levey AI; Padala KP; Herrmann N
Am J Geriatr Psychiatry; 2023 Dec; 31(12):1077-1087. PubMed ID: 37385898
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of methylphenidate for the treatment of apathy in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled studies.
Lee CW; Chen JY; Ko CC; Chuang MH; Tsai WW; Sun CK; Hung KC
Psychopharmacology (Berl); 2022 Dec; 239(12):3743-3753. PubMed ID: 36243827
[TBL] [Abstract][Full Text] [Related]
15. Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study.
Clark ED; Perin J; Herrmann N; Brawman-Mintzer O; Lanctôt KL; Lerner AJ; Mintzer J; Padala PR; Rosenberg PB; Sami S; Shade DM; van Dyck CH; Porsteinsson AP;
Alzheimers Dement (N Y); 2023; 9(3):e12403. PubMed ID: 37538343
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate and Other Pharmacologic Treatments for Apathy in Alzheimer's Disease.
Andrade C
J Clin Psychiatry; 2022 Feb; 83(1):. PubMed ID: 35120284
[TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of modafinil for the treatment of apathy in individuals with mild-to-moderate Alzheimer's disease.
Frakey LL; Salloway S; Buelow M; Malloy P
J Clin Psychiatry; 2012 Jun; 73(6):796-801. PubMed ID: 22687392
[TBL] [Abstract][Full Text] [Related]
18. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
[TBL] [Abstract][Full Text] [Related]
19. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
[TBL] [Abstract][Full Text] [Related]
20. Bupropion for the Treatment of Apathy in Alzheimer Disease: A Randomized Clinical Trial.
Maier F; Spottke A; Bach JP; Bartels C; Buerger K; Dodel R; Fellgiebel A; Fliessbach K; Frölich L; Hausner L; Hellmich M; Klöppel S; Klostermann A; Kornhuber J; Laske C; Peters O; Priller J; Richter-Schmidinger T; Schneider A; Shah-Hosseini K; Teipel S; von Arnim CAF; Wiltfang J; Jessen F
JAMA Netw Open; 2020 May; 3(5):e206027. PubMed ID: 32463470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
